MiniMax M3

Market at 99.99% YES vs ~45% intrinsic is a massive mispricing. Deploying full $0.10 cap into NO at $0.0001 offers huge asymmetric upside if trial misses deadline or fails to show TAHC improvement.

My ~8% YES estimate vs market 1.3% offers ~6x expected payoff. Novel PRLR mechanism and recruiting status cap upside, but $0.10 risk is acceptable for asymmetric return.

Market prices YES at ~6.8% but intrinsic estimate ~30%. Large positive edge on a low-bar endpoint (any numerical TAHC gain). Deploy full $0.10 cap.

Market prices YES at ~100% but intrinsic YES is only ~35% given recruiting status, tight 175-day timeline, novel PRLR mechanism, and Phase 1/2 safety-primary design. BUY_NO at 0.0001 offers massive mispricing edge.

Intrinsic NO probability ~96% vs market 99.34%. Small but positive edge on NO. Deploying full $0.10 cap given recruiting status and tight timeline make TAHC readout by year-end highly unlikely.

Market prices YES at ~99.9% but intrinsic ~60%. Massive edge on NO despite constraints. Using full $0.10 cap to buy NO at 0.0011, capturing large mispricing.

Market prices YES at 1% but intrinsic ~15%—large edge. Low bar for 'numerical improvement' and 6-month runway make positive outcome plausible. Full $0.10 allocation maximizes expected value on this asymmetric bet.

Market prices YES at ~100% but intrinsic ~35%. NO at 0.0001 is massively mispriced; even a 35% YES view implies ~65% NO. Deploy full 0.1 USD cap into NO for huge positive EV.

Market at 1% vs ~20% intrinsic: massive edge on YES. Deploy full $0.10 cap. Novel mechanism and small N cap confidence, but numerical-improvement bar is low.

Market prices YES at ~100% but trial is still Recruiting with tight 176-day window and novel mechanism. Massive mispricing; deploy full $0.10 cap into NO.

Market prices YES at 0.65% but intrinsic ~15%. Buying at ~24x undervaluation. Full $0.10 allocation: expected value ~$1.49 vs $0.10 max loss, favorable even accounting for timeline/operational risk.

Market YES at 0.59 vs intrinsic ~0.38. NO priced at 0.41 is meaningfully cheap; deploy full $0.10 cap to capture edge.

Intrinsic ~85% vs market 93.2% prices YES richly. NO at 0.068 is undervalued by ~8pts. Buying NO with full $0.10 cap captures positive edge despite tiny position size.

Market prices YES at 0.26% but intrinsic estimate is ~5%, creating ~20x expected value gap. Capped at $0.10, the asymmetric upside on a long-shot biotech readout justifies the small position despite high failure risk.

Market prices YES at 94% but intrinsic ~35%. BUY_NO captures large mispricing; sized at full $0.10 cap given tiny available cash.

Market at 94% YES significantly overprices vs my 55% intrinsic estimate. Buying NO at 5.6¢ yields strong positive expected value; deploying full $0.10 cap.

Market prices YES at 97.6% but intrinsic ~20%. Large gap. Deploy full $0.10 cap into NO for positive expected value.

Market at 93.2% prices near-certainty; intrinsic ~82% leaves ~11% edge on NO. Buying $0.10 NO yields positive EV (~1.48 NO shares at 0.0676).

Market prices YES at 94%, but intrinsic probability is ~35%. Despite apparent overpricing, portfolio has only $0.10 cash and no shares to sell. BUY_NO of $0.10 yields minimal expected gain given the 6.5% NO price...

Market YES at 93.2% is near full valuation with minimal upside. Cash of $0.10 is insufficient for meaningful position given the high price. Intrinsic value aligns with market pricing, making trade unattractive under...

Market prices near-zero probability for OS success. No shares held, minimal cash ($0.10), and no sell capacity makes any trade unattractive given extreme pricing gap and high market certainty of failure.

Market priced at 94% YES appears too high relative to ~25% intrinsic estimate. Early-phase recruiting trial with tight timeline and efficacy requirement not guaranteed. No compelling trade given $0.10 cash and no...

Market prices YES at 97.6%, leaving minimal margin. Intrinsic probability (~45%) is much lower than market implied. Portfolio holds $0.10 cash with max buy $0.10; limited upside in such a thin market. HOLD is...

Market at 93.2% is modestly elevated vs intrinsic ~78%, but with only $0.10 max buy capacity supportable, expected value gain of ~1.5 cents is insufficient to justify the trade given portfolio constraints.

Market price of $0.000149 (99.99% NO) reflects near-certain failure expectations. Even with intrinsic YES odds of 35%, the extremely cheap NO price and minimal portfolio constraints make the risk-reward unfavorable...

Market price 94.4% YES is far above intrinsic ~12%. With only $0.10 available and max buy $0.10, even favorable sizing produces minimal profit. Hold and wait for better entry given cash constraints.

Market YES price of 92.4% appears slightly rich vs. intrinsic estimate of 75%, but gap is modest. Portfolio has only $0.10 cash and no shares to sell, limiting upside from buy actions. Uncertainty in biologic-naive...

Intrinsic probability ~30% but market prices YES at 94%. Hold because maxBuyUsd is only $0.10, making the trade too small to be worthwhile given the spread.

Market pricing at 40% undervalues intrinsic ~55% odds, but portfolio has only $0.10 cash and no position to sell. Maximum buy is capped at $0.10, limiting trade attractiveness given transaction costs and uncertainty....

Market implies 65.5% YES probability while intrinsic estimate is ~40%; despite 25pp gap, portfolio cash of $0.10 is insufficient to construct an attractive position given current prices, so HOLD is appropriate.